Algorithms for grading acute graft-vs.-host disease (GVHD) are inaccurate in assessing mortality risk. We developed a method to predict mortality by using data from 386 patients with acute GVHD. From the onset of GVHD to day-100, GVHD manifestations were scored for the skin, liver, upper and lower gastrointestinal tract, and data were recorded for immunosuppressive treatment, performance, and fever. Logistic regression models predicting non-relapse mortality at day-200 were developed with data from 193 randomly-selected patients and then validated in the remaining 193 patients. Clinical parameters were grouped to optimize predictive accuracy measured as the area under a receiver-operator characteristic (ROC) curve. The optimal model included the total serum bilirubin concentration, oral intake, need for treatment with prednisone, and performance score. When the overall burden of GVHD was measured by using average acute GVHD activity index (aGVHDAI) scores for each patient in training and validation data sets, areas under ROC curves were 0.87 and 0.85, respectively. Contour lines were generated to reflect the predicted non-relapse mortality at day-200 as a function of current aGVHDAI scores.
INTRODUCTION
Acute graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic cell transplantation, affecting ~60% of recipients of allogeneic donor cells following myeloablative conditioning regimens. 1, 2 Grading of GVHD can serve a variety of purposes, including retrospective assessment of peak severity, real-time assessment of severity at pre-specified time points, determination of the need for treatment, assessment of treatment response, prognostication for survival, and evaluation of new methods to prevent GVHD in prospective studies. The most widely used grading systems for grading acute GVHD represent variations of criteria originally proposed by Glucksberg et al. in 1974 on the basis of clinical intuition. 3, 4 Variations of the Glucksberg system have been published to improve its utility for specific purposes. 5, 6 Although these grading systems have descriptive validity and a general relationship to outcome, several problems hamper the application of current grading systems for the purpose of predicting outcomes among patients with acute GVHD: (1) Relation of disease severity in skin, gut, and liver to outcome was never evidence-based, but instead reflected the judgment of experienced clinicians. 3 (2) Assignment of a peak GVHD score is done in retrospect; clinicians cannot use the current grading system for peak score in real-time. ( 3) The systems do not account for the time to response after treatment. Thus, patients whose symptoms resolve completely after a short course of immunosuppressive therapy may be scored identically to patients who require months of high-dose immunosuppressive drug therapy to control symptoms. (4) Significant interobserver errors exist in the current grading systems, largely because of subjective biases. 7-10 (5) Assignment of grade IV GVHD is often used descriptively to indicate that GVHD caused a patient's death, irrespective of the severity of symptoms. In this situation, the grading reflects the outcome and cannot be used to predict the outcome. Indeed, neither of the grading algorithms described by Przepiorka et al 4 or Rowlings et al 5 performs well as a prognostic tool, as neither explains much of the variation in either early or late survival. 10 We have developed a new system for assessing the severity of acute GVHD that scores GVHD activity at 10-day intervals to day-100 following transplant. This acute GVHD Activity Index (aGVHDAI) is scaled from 0 to 100, with the intent of providing clinicians with a means of predicting outcome in real-time on the basis of current GVHD activity, and providing investigators with an evidence-based measure of the burden of acute GVHD over time. Our aGVHDAI was designed to predict day-200 non-relapse mortality. To develop our activity index, 386 patients with chronic myeloid leukemia who had allogeneic HCT from unrelated donors were randomly divided into a Training Data Set and a Validation Data Set. Signs and symptoms of acute GVHD were recorded to day-100; a model predicting day-200 non-relapse mortality was optimized using receiver-operator characteristic curves, and the final model was applied to the validation set of patients to assess the reproducibility of the aGVHDAI in predicting mortality. We then prepared a graphic that allows clinicians to predict day-200 non-relapse mortality on the basis of the calculated aGVHDAI at points in time up to day-100 post HCT.
METHODS
Patient selection. One of us (EWP) randomly selected 411 patients with chronic myeloid leukemia who had a first allogeneic HCT from unrelated donors with 0, 1, or 2 or more allele disparities at HLA-A, B, C, DRB1, DQB1 as determined by sequence-based methods. 11 All patients received conditioning therapy with cyclophosphamide (CY, 120 mg/kg) and total body irradiation (TBI, median dose 12 Gy), followed by bone marrow infusion, between 1987 and
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Prophylaxis against infections during this time period varied, as described previously. 1 These patients had been retrospectively graded for acute GVHD by one observer (PJM), but these grades were not revealed to those compiling the aGVHDAI until completion of the validation process. Among the 411 patients in the cohort, 386 developed grade I -IV acute GVHD and were included in this analysis. Review of patient charts and research records was carried out under the aegis of a protocol approved by the Institutional Review Board.
Assessment of the severity of GVHD by conventional grading. A date of onset of acute GVHD and a descriptive grade for its severity had been previously determined by one observer (PJM), using methods as described by Przepiorka et al., with minor modifications. 1, 4 Biopsies of skin, gut, and liver were done in 89%, 27%, and 2% of patients, respectively; overall, 93% of subjects had biopsies. The diagnosis of acute GVHD of the skin was established by the development of a characteristic erythematous or morbilliform rash first appearing generally between 10 and 70 days after transplantation. Overall grade I GVHD denoted stage 1 -2 skin involvement with no liver or gut involvement, indicating that the prophylactic immunosuppressive regimen administered after the transplant was not sufficient to prevent all manifestations of acute GVHD, but in most cases, the disease resolved spontaneously without treatment. Overall grade II GVHD denoted stage 3 skin involvement or stage 1 liver or gut involvement, indicating that the prophylactic immunosuppressive regimen administered after the transplant was not sufficient to prevent manifestations of acute GVHD, but glucocorticoid treatment after the onset of GVHD was generally sufficient to control the disease. Overall grade III GVHD denoted stage 4 skin involvement or stage 2 -4 liver or gut involvement without GVHD as a major contributing cause of death, indicating that the prophylactic immunosuppressive regimen was not sufficient to prevent manifestations of acute GVHD and that additional treatment after the onset of GVHD did not readily control the disease. Overall grade IV GVHD denoted stage 4 skin involvement or stage 2 -4 liver or gut involvement with GVHD as a major contributing cause of death, indicating that the disease was resistant to both the prophylactic immunosuppressive regimen and any additional treatment after the onset of the disease.
Parameters of acute GVHD used for creation of an activity index. We assessed the severity of seven GVHD parameters in each 10-day time period from day-0 to day-100, starting with the period in which the onset of GVHD occurred. Most of the raw data had been prospectively collected at the time of transplant by our Clinical Nutrition, Nursing, and Pharmacy Sections, for example, daily oral caloric intake, diarrheal volumes, body temperature, and medications administered. Physicians caring for patients wrote daily progress notes and dictated interim summaries according to a uniform format, enabling us to assign patient performance scores, as described below.
We assigned a unique letter score for each degree of abnormality within each parameter, except for liver scoring, which used total serum bilirubin values. The purpose of using letters rather than numbers was to avoid the bias of numerical values and to facilitate future research regarding the relative accuracy of various weightings of each letter score.
Skin GVHD was scored by the nature and extent of abnormality during each 10-day period, as the worst score during this time. This scoring system excluded rashes of known viral or other origin such as varicella zoster virus, herpes simplex virus, and drug-related rashes. The letters {a, b, and c} described a macular erythematous rash involving <1/3, 1/3 to 2/3, and >2/3 of the body surface, respectively. The letters {d, e, and f} and {g, h, k} similarly described maculopapular rashes and desquamation, respectively. Liver GVHD was scored by the maximum total serum bilirubin concentration in mg/dL during each 10-day interval after the onset of acute GVHD, rounded to the nearest whole number. If the total serum bilirubin concentration was <1 mg/dL, then a score of zero was recorded. Total serum bilirubin concentrations >15 mg/dL were recorded as 15, since previous studies have shown that bilirubin concentrations >15 mg/dL do not predict a worse prognosis than values of 15. 15 No adjustments were made for the presence of concurrent liver dysfunction caused by diseases other than GVHD.
Upper gut GVHD was scored by reviewing data on daily caloric intake, as recorded by the FHCRC Clinical Nutrition service during the post-transplant period, and by clinical symptoms described in daily progress notes. These data compare the lowest oral caloric intake per day with the therapeutic caloric goal for that day. A score of zero was given if oral calories were ≥90% of patient requirements and the patient had a normal appetite during the 10-day period. A letter score of {m} described oral calories 70% -90% of patient requirements and mild anorexia or nausea; {n}, oral calories 40% -70% of patient requirements and moderate anorexia, nausea, and vomiting; and {p}, oral calories <40% of patient requirements with poorly controlled symptoms. 16, 17 Lower gut GVHD was scored by reviewing daily stool volumes as recorded in chart notes by the Nursing and Clinical Nutrition services and by descriptions of diarrhea in daily progress notes.
The score for each 10-day period reflected the highest daily stool output during this interval. A score of zero was given if the largest stool volume in the interval was <200 mL/day and there was no record of diarrhea. A letter score of {s} described stool volumes 200-300 mL/day and a history of loose stools; {t}, stool volumes 300-500 mL/day and frequent diarrhea; and {u}, stool volumes >500 mL/day and unrelenting diarrhea.
Immunosuppressive therapy during each 10-day period was scored as the most intensive treatment prescribed to control GVHD. A score of zero denoted no immunosuppressive drugs. A letter score of {y} meant that only prophylactic drugs such as cyclosporine or tacrolimus were prescribed during that period. {w} and {x}meant that prednisone was prescribed at doses of <1 mg/kg/day and 1-2 mg/kg/day, respectively. {y} meant that the patient had received secondary therapy to control GVHD during the 10 day period in question, for example, prednisone >2 mg/kg/day, antithymocyte globulin, sirolimus, or anti-T-cell monoclonal antibodies.
Fever scoring referred to the highest fever documented during each 10-day interval, with zero assigned to patients whose temperature was normal (<37.2 o C) throughout this period, the letters {AA} for any recorded temperature from 37.2 to 38.5 o C; and {BB} for any recorded temperature over 38.5 o C.
Performance status during each 10-day period was scored using a modification of the Eastern Cooperative Oncology Group system. 18 Interim and discharge summaries from the FHCRC electronic database provided dates of admission and discharge between inpatient and outpatient status. Performance scores were based on narratives by patient-care providers, where zero described outpatients who felt well and fully active; {CC}, outpatients who were unwell and fully ambulatory, but limited in strenuous activity; {DD}, inpatients who were unwell, ambulatory, capable of self-care, and spending more than 50% of waking hours out of bed;
{EE}, inpatients who were unwell, limited in their self-care, and spending more than 50% of time in bed; and {FF}, inpatients who were completely disabled, providing no self-care, and confined to bed. Rather than simply including the most significant factors, we were interested in optimizing the area under a receiver-operator characteristic curve (ROC) 19 for a scoring algorithm that best Throughout the modeling exercise, GVHD parameters were grouped in different ways to optimize the scoring system's predictive abilities, while using the fewest parameters possible.
Two basic models were developed, the first for evaluation of the burden of acute GVHD across time. For this model, we used average aGVHDAI scores over all ten-day intervals from the time of onset of GVHD to death, departure from our center, or day-100, whichever occurred first. These data were used for model fitting and calculation of coefficients that could be used as score weights. A second model was developed for real-time prediction of non-relapse mortality by day-200. For this model, the current value of each factor from each interval was included in a generalized estimating equation formulation of the logistic regression model, to account for the correlated longitudinal data from each subject. 20 All coefficients were positive (that is, we observed increased risk of non-relapse mortality for higher categories of all covariates). Scaling was carried out by dividing the coefficients by the sum of the coefficients (using only the highest category for factors with multiple levels) and multiplying this proportion by 100. Thus, the score could range from 0 to 100, with 100 being worst. Once the weights were obtained from each model, we were able to construct a single weighting system by averaging the weights for the two models, without marked change in the overall accuracy of the aGVHDAI. We found that, within a similar realm of weights, the difference in areas under the ROC curves rests on how the scores from each interval are used, either as a average over all intervals to summarize experience for each subject (research use), or as an individual value from each interval, to predict NRM by day-the final weighting system was determined, the aGVHDAI was independently evaluated in the Validation Data Set.
For each patient in the combined data sets (N=386), the average GVHDAI was compared to the peak GVHD grade that had been recorded independently. We also examined the accuracy of GVHD grading according to Przepiorka et al 4 and Rowlings et al 5 for predicting day-200 mortality. In this analysis, overall grades were derived entirely from organ scores, without considering mortality. We then evaluated the true and false positive rates when these overall grades were dichotomized at each possible level for predicting NRM in the Validation Data Set (N=193). A non-parametric method was used to evaluate the areas under ROC curves defined by these scoring systems as compared to the area under the ROC curve for the average aGVHDAI in the Validation Data Set. 21 To illustrate the predictive value of the current value of aGVHDAI from different time intervals, we fit a smooth cubic spline curve in logistic regression models for the probability of NRM by day-200 as a function of the calculated scores within different time intervals. Data Sets, respectively; the remaining patients received cyclosporine. **'Other' refers to a CD25-specific immunotoxin for 4 and 7 patients and to a humanized CD25-specific antibody for 16 and 18 patients from the Training and Validation Data Sets, respectively.
RESULTS

Demographics
Development of an aGVHDAI in the Training Data Set of 193 patients.
Throughout the modeling exercise, the aim was to group the parameters of aGVHD in different ways to optimize the scoring system's predictive qualities, while using the fewest parameters possible. For the optimal logistic regression model, each patient's experience was summarized as the average of all ten-day interval aGVHDAI scores. Only parameters reflecting liver dysfunction, oral caloric intake, need for prednisone or secondary immunosuppressive therapy, and performance score entered the optimal model (Table 2) . A similar model to determine weights for use when predicting NRM based on the score in each time interval was fit. Since the two models gave similar weights (data not shown), we elected to use a common weighting system based on the average from these two models (Table 2 ). There was little loss in the area under the ROC curve for either use of the score with this simplification (data not shown). There was no significant improvement in the area under the ROC curve when we added age as a continuous variable and HLA disparity (10/10 vs. <10/10) to the optimal model for predicting NRM (p=0.51).
Mild jaundice (total serum bilirubin concentration 2-4 mg/dL) conferred an increased risk of non-relapse mortality, and deeper jaundice (≥5 mg/dL) a greater risk, but extreme bilirubin concentrations did not enter the model. Neither the severity of skin GVHD nor the amount of diarrhea entered the model. Uncontrolled symptoms of anorexia, nausea, and vomiting, with oral caloric intake <40% of caloric requirements, but not less severe symptoms, carried increased risk of mortality. Any dose of prednisone, or more intensive immunosuppressive therapy, was associated with an increased risk of non-relapse mortality, as was poor performance status (Table   2) . Figures 1A and 1B show the ROC curves with the weights shown in Table 2 for the Training Data Set; the area under the curve is 0.87 when prediction of day-200 non-relapse mortality is based on average aGVHDAI scores for each patient ( Figure 1A ) and 0.76 when based on scores for each interval ( Figure 1B ). 
org From
Validation of the aGVHDAI in an independent data set of 193 patients. Receiver-operator characteristic curves that resulted from the application of the weights shown in Table 2 to calculate the aGVHDAI in the randomly selected Validation Data Set are shown in Figure 1 . Figures 1A' and 1B' show the ROC curves for the Validation Data Set; the area under the curve is 0.85 when prediction of day-200 non-relapse mortality is based on average aGVHDAI scores for each patient ( Figure 1A' ) and 0.74 when based on scores for each interval (Figure 1B') .
Comparison of the average aGVHDAI values with conventional GVHD grading.
Conventional GVHD grades were compared to the average aGVHDAI values for all patients in (Table 3) . A vs. B-D 100% 99%
A-B vs. C-D 81% 74%
A-C vs. D 21% 2%
The points associated with each pair of true positive and false positive rates are shown in Figure   3 along with the ROC curve for the average aGVHDAI in the Validation Data Set. The area under the ROC curve for each of these two peak value-based systems is significantly lower than the area under the ROC curve for the average aGVHDAI (p <0.001 for both comparisons). grading systems, which do not account for response or lack of response after treatment. [3] [4] [5] [6] Unlike current descriptive scoring systems that include death as a criterion for grade IV GVHD, the aGVHDAI does not consider death, since this scoring system was developed for the specific purpose of predicting the risk of death within the first 200 days after HCT. The aGVHDAI is a more accurate predictor of non-relapse mortality than the grading systems according to Przepiorka et al 4 or Rowlings et al. 5, 10 Before this index can be widely used to guide clinical decision-making, however, it must be validated at other centers, in a wider range of patients. We do not envision this index as a fixed formula, but rather as the beginning of a process of
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Although the components that were considered for the logistic regression models in this study were complex, the final elements of the aGVHDAI are relatively simple. For example, it is not necessary to measure stool volumes, or estimate body surface area of skin involved with GVHD, as neither parameter entered the model. And since only the most extreme upper gut symptoms entered the model, scoring the upper gut is straight forward if a patient had little oral intake while constantly vomiting during a day of the interval in question. Calculation of oral intake as a percent of caloric requirements may be needed if patients have only anorexia as a manifestation of GVHD and the oral intake is uncertain. 17 Since liver dysfunction is a wellrecognized contributor to mortality after allogeneic transplant 15, 24 , it was not surprising to find total serum bilirubin parameters as components of the aGVHDAI. The doses of immunosuppressive drugs needed to control GVHD did not improve the correlation with the risk of non-relapse mortality over a binary assessment as to whether any therapeutic dose of immunosuppressive drugs was needed to control symptoms.
We envision that the aGVHDAI could be used for two purposes. One would be to assess the risk of a fatal outcome in a patient with acute GVHD in real time, using the graphic in Figure   4 . Patients at high-risk should be considered for more aggressive treatment or for entry into clinical intervention trials, thereby allowing patients to be stratified according to the risk of mortality. Patients at low risk may be spared the morbidity of unnecessary continued high-dose immunosuppressive therapy. A second purpose would be to measure the burden of acute GVHD across time, as a research tool to assess the efficacy of prevention and treatment in clinical trials.
Because standard GVHD grading is an inaccurate predictor of survival 10 , clinical trials that use
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The aGVHDAI described here was inspired by the Crohn's Disease Activity Index (CDAI), a system for scoring the severity of an intestinal disorder that has skin, liver, and extraintestinal manifestations, similar to those of acute GVHD. 25 Whereas the CDAI was developed by using an expert panel's definitions of severity of disease, the aGVHDAI used day-200 non-relapse mortality for validation. Validation according to mortality avoids using manifestations of disease to predict disease severity. On the other hand, using day-200 mortality to capture the severity of acute GVHD across time has the disadvantage that mortality reflects not only GVHD but also residual toxic effects of the conditioning regimen, immunosuppressive drug treatment for GVHD, and infections. Because GVHD does not develop in a vacuum, we think it reasonable to score the disease by examining the totality of its effects, including those of the drugs used to treat the disease and the emergent infections that arise as a consequence. Like the CDAI, which was re-calibrated by an expert panel to be sure that the components of the index and their weightings had not changed over time 26 , the aGVHDAI will have to be recalibrated at time intervals, and also examined in cohorts of patients who were not represented in the 386-patient panel from which the activity index was derived. In particular, it would be of interest to determine how well the aGVHDAI might apply to a larger cohort of pediatric patients and to those who have HCT after non-myeloablative conditioning regimens.
In summary, we have developed and validated a disease activity index that measures the burden of acute GVHD across time with day-200 mortality as the endpoint. The aGVHDAI is easy to calculate at 10-day intervals from the highest total serum bilirubin concentration, severity of upper gut symptoms, need for immunosuppressive drugs, and performance score. This index
